In the context of empiric therapy for suspected neonatal meningitis with meningitis risk or local resistance, what is a commonly recommended combination therapy?

• A. Vancomycin plus a third-generation cephalosporin (e.g., cefotaxime)
• B. Ampicillin alone
• C. Gentamicin monotherapy
• D. Cefazolin alone

Answer: (A)

Starting empiric therapy for suspected neonatal meningitis focuses on broad coverage against both the common pathogens and any resistant organisms until culture results come back. Vancomycin targets resistant Gram-positive bacteria, including MRSA and coagulase-negative staphylococci, which can be involved in neonatal meningitis, especially in hospital settings. Pairing it with a third-generation cephalosporin such as cefotaxime provides robust activity against Gram-negative pathogens like E. coli and Klebsiella and offers good penetration into CSF, which is essential for treating meningitis. In neonates, cefotaxime is favored over ceftriaxone due to the risk of bilirubin displacement and kernicterus. Regimens like ampicillin alone or gentamicin alone don’t offer the same breadth of coverage or reliable CSF penetration for meningitis, making vancomycin plus a third-generation cephalosporin the commonly recommended empiric choice.